P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

The anaplastic lymphoma kinase (ALK) fusion oncogene is observed in 3%–5% of non-small cell lung cancer (NSCLC). Crizotinib and ceritinib, a next-generation ALK tyrosine kinase inhibitor (TKI) active against crizotinib-refractory patients, are clinically available for the treatment of ALK-rearranged...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:EBioMedicine
Glavni autori: Katayama, Ryohei, Sakashita, Takuya, Yanagitani, Noriko, Ninomiya, Hironori, Horiike, Atsushi, Friboulet, Luc, Gainor, Justin F., Motoi, Noriko, Dobashi, Akito, Sakata, Seiji, Tambo, Yuichi, Kitazono, Satoru, Sato, Shigeo, Koike, Sumie, John Iafrate, A., Mino-Kenudson, Mari, Ishikawa, Yuichi, Shaw, Alice T., Engelman, Jeffrey A., Takeuchi, Kengo, Nishio, Makoto, Fujita, Naoya
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2015
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4739423/
https://ncbi.nlm.nih.gov/pubmed/26870817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2015.12.009
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items